Aptevo Reports 21% of Frontline AML Patients Reached Transplant on Triplet
Aptevo said 10 of 47 evaluable newly diagnosed AML patients receiving mipletamig with venetoclax and azacitidine proceeded to allogeneic stem cell transplant, compared with 0.7% reported with VEN+AZA in VIALE-A. Dose optimization in RAINIER is expected to conclude by year-end 2026.